MONDAY, July 23 (HealthDay News) — A genetic score can modestly improve the prediction of which men are likely to have positive biopsies for prostate cancer after an initial negative biopsy, according ...

UnitedHealthcare singles out mdxheath’s GPS test as its only commercially-covered test to risk stratify men newly diagnosed with localized prostate cancer IRVINE, CA, and HERSTAL, BELGIUM – February ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests - Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris - can help doctors make better decisions ...

TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

Mdxhealth and University of Oxford to validate GPS test in largest randomized trial of treatment effectiveness in patients with localized prostate cancer IRVINE, CA – January XX, 2026 (GlobeNewswire) ...

TAMPA, Fla. (Jan. 24, 2025) — A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help ...

New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men. MENLO PARK, Calif., Nov. 20, 2025 /PRNewswire/ -- MyOme, ...

India's Prime Minister Narendra Modi will meet his Malaysian counterpart Anwar Ibrahim on Sunday, as the two countries look to bolster trade and explore potential collaborations in semiconductors, ...

Analyzing a tumor’s genes can predict which prostate cancers won’t need additional treatment and which cases require more intensive therapies. Watchful waiting is a common strategy for treating ...